|
Accrued
Expenses, summarized by major category, as of March 31, 2021 and December 31, 2020 consist of the following:
Schedule of Accrued Expenses
| |
|
March 31, 2021 |
|
|
December 31, 2020 |
|
| Payroll and incentives |
|
$ |
303 |
|
|
$ |
1,094 |
|
| General and administrative expenses |
|
|
234 |
|
|
|
280 |
|
| Research and development expenses |
|
|
683 |
|
|
|
778 |
|
| Deferred revenue and other deferred liabilities * |
|
|
186 |
|
|
|
643 |
|
| Total |
|
$ |
1,406 |
|
|
$ |
2,795 |
|
| * |
At
December 31, 2020, approximately $577 thousand is the remaining balance of the CFF Agreement’s deferred liability and approximately
$67 thousand is deferred revenue related to the Genentech Agreement. At March 31, 2021, approximately $153 thousand is the remaining
balance of the CFF Agreement’s deferred liability and approximately $33 thousand is deferred revenue related to the Genentech
Agreement. (See Note 9 – Collaboration Agreements, Licenses and Other Research and Development Agreements). |
|